Randomized Study Comparing CMF and Goserelin + Tamoxifen in Premenopausal Receptor-positive Patients

Inclusion Criteria: * Premenopausal patients with histologically verified, lymph node-negative (pT1c-pT3) or lymph node-positive (pT1a-pT3) breast cancer * Hormone receptor-positive status * More than 6 histologically examined lymph nodes * Laboratory parameters 1. hematopoiesis: \> 3500/µl leukocytes, \> 100,000/µl thrombocytes 2. renal function: creatinin \< 1.5mg % 3. hepatic function: GOT \</= 2.5 x UNL 4. bilirubin: \< 1.5mg % 5. metabolic parameters: Na, Ca, K in normal range, normal level of blood sugar 6. blood coagulation: PZ \> 60% * Concluded healing process following surgery * \</= 4 weeks interval since surgery * Informed consent Exclusion Criteria: * T4 carcinoma; inflammatory breast cancer, carcinoma in situ * Simultaneous or sequential bilateral breast cancer * Preoperative tumor-reducing radiotherapy or preoperative tumor-specific medical treatment * Male patients * Pregnancy or lactation * Lacking compliance or understanding of the disease * General contraindication against cytostatic treatment * Serious concomitant disease preventing implementation of adjuvant therapy or regular follow-up * Second carcinoma or status post second carcinoma (except for curatively treated squamous cell carcinoma of the skin or cervical carcinoma in situ)